Dermatologists TJ Chao and Kristine Kucera are shedding light on the latest advancements in plaque psoriasis treatment, particularly focusing on the introduction of TYK2 inhibitors. They emphasize the increasingly important role of physician assistants in managing plaque psoriasis and highlight the recognition of the condition as a systemic disease.
The discussion delves into the lab and monitoring requirements associated with TYK2 inhibitors such as deucravacitinib, as well as a comprehensive overview of both short- and long-term clinical trial data. Chao and Kucera provide valuable insights into patient selection and the patient experience with oral systemic agents, offering guidance on selecting the most suitable therapies in the ever-growing treatment landscape.
This informative conversation serves as a valuable resource for healthcare professionals seeking to stay up-to-date on the latest developments in plaque psoriasis treatment.
